Financial Information

These accounts have been produced by chartered accountants and reviewed by our Statutory Auditor Deloitte & Associates.

Revenue 2010
.
Expenses 2010

EURORDIS Expenses 2010

Collapse All
Expand All
Domain Amount Percentage
Staff 1,551,659 € 44 %
Volunteers 375,990 € 11 %
Travel and subsistence 378,186 € 11 %
Services 998,214 € 28 %
Purchase 106,357 € 3 %
Financial and insurance expenses 5,978 € 0 %
Sub-total 3,416,384 € 97 %
Contingency and loss provisions 102,433 € 3 %
Commitment on assigned income n/a n/a
Total Expenses 3,518,817 € 100%

EURORDIS Revenue 2010

Collapse All
Expand All
Domain Amount Percentage
Patient Organisations 884,874 € 24 %
Volunteers 375,990 € 10 %
European Commission 1 379,775 € 38 %
National authorities 95,184 € 3 %
Corporate funding 546,811 € 15 %
Foundations and NPOs 130,517 € 4 %
Miscellaneous 139,958 € 4 %
Sub-total 3,553,109 € 98 %
Recovery of provisions 51,757 € 1 %
Report of non-used income 33,500 € 1 %
Total Revenue 3,638,366 € 100 %

EURORDIS Corporate Revenue 2010

Collapse All
Expand All
Company Amount % of total Revenue
ALEXION PHARMA 23,300 € 0.66%
AMGEN 5,000 € 0.14%
AMICUS 5,000 € 0.14%
BAXTER 10,000 € 0.28%
BAYER SCHERING 15,000 € 0.42%
BIOMARIN 10,000 € 0.28%
CELGENE 51,500 € 1.45%
CHIESI FARMACEUTICI 5,000 € 0.14%
CLOVIS ONCOLOGY, INC. 5,000 € 0.14%
CSL BEHRING 60,000 € 1.69%
DOMPE 5,000 € 0.14%
FOLDRX Pharmaceuticals 5,000 € 0.14%
GENZYME 33,000 € 0.93%
GILEAD SCIENCES INT LTD 10,000 € 0.28%
GSK 15,000 € 0.42%
HELSINN 7,700 € 0.22%
INTERMUNE 5,000 € 0.14%
LFB BIOMEDICAMENTS 11,960 € 0.34%
MERCK SERONO 5,000 € 0.14%
NOVARTIS 60,000 € 1.69%
ORPHAN EUROPE 8,300 € 0.23%
PALO ALTO INSTITUTE 5,451 € 0.15%
PFIZER PIO 25,000 € 0.70%
PHARMA MAR 5,000 € 0.14%
PTC THERAPEUTICS 5,000 € 0.14%
SERVIER I.R.I.S. 5,000 € 0.14%
SHIRE 19,600 € 0.55%
SIGMA TAU 75,000 € 2.11%
SWEDISH ORPHAN 7,500 € 0.21%
SYNAGEVA 5,000 € 0.14%
TAKEDA 18,500 € 0.52%
TALECRIS 10,000 € 0.28%
VIFOR PHARMA 10,000 € 0.28%

In addition to the organisation accredited (on the right hand side), EURORDIS would like to gratefully ackowledge the generous support of the following organisations and companies for their highly valued support in the past year

The E-Newsletter and Rare!Together Project

EURORDIS is grateful to The Medtronic Foundation for their financial support for the EURORDIS E-Newsletter and
the Rare!Together project

Medtronic Foundation Logo

EURORDIS Online Communities

EURORDIS is grateful to the Alexion, Celgene LeeM, and NORD for their financial support to
the Online Patient Communities project.

Alexion Logo
Celgene Logo
LEM Logo
NORD Logo

POLKA Project Co-Funding

CSL Behring
Sigma-tau logo
Novartis logo

and In-kind contributions from:

Fundació Doctor Robert Universitat Autònoma de Barcelona Casa Convalescència
National Commissioning Group, NHS, UK

EURORDIS Summer School for Patients Advocates

 DIA (Drug Information Association) Philanthropy Programme

and In-kind contributions from:

Fundació Doctor Robert Universitat Autònoma de Barcelona Casa Convalescència

Unrestricted Financial Support

PAI logo

European Conference on Rare Diseases - ECRD 2010 Krakow

EURORDIS is grateful to the organisations listed below for their financial support, including fellowships for patient representatives:

alexion
Bayer Schering Pharma AG
Genzyme
GSK
Helsinn
Orphan%20Europe
Shire
SOBI Logo - 3.5 kb
Takeda logo

and In-kind contributions from:

the Medical School of the Jagiellonian University

Round Table of Companies

The EURORDIS Round Table of Companies (ERTC) was created to establish a long-term educational relationship between EURORDIS and those companies having an interest in orphan drugs, treatments, medical devices, food supplements and health services for people living with rare diseases. This relationship is driven by the Principles stated in the Round Table Code of Conduct and according to EURORDIS Policy on Financial Support by Commercial Companies

Eurordis is grateful for the support of the members of the EURORDIS Round Table of Companies

Breakdown of EURORDIS Corporate Funding by company and by project More information